

Review of: "Progression-free survival as a primary end-point: Counting the cost"

Sara Cecilia Altuna Mujica

Potential competing interests: No potential competing interests to declare.

This is an interesting debate that has been gaining momentum in recent years. With the rising costs of oncology drugs and overall care, with marginal benefits from experimental as well as real-world data, we have to question whether we're providing the best options for all the people involved, including stakeholders, hospital staff and even insurance companies who have to carry on with the costs. I find this article adds to the conversation in a very concise and illustrated manner, and I would like to congratulate the author for his efforts in this paper.